CD19 and prostate carcinoma: NOD scid gamma (NSG) mice were engrafted s.c. with the human STEAP1-positive prostate cancer cell line 22Rv1 and, once the tumors were palpable, treated with STEAP1 CAR T cells, CD19 CAR T cells, or NT T cells.